{
  "id": "fc1e9031bc655011",
  "title": "Immunofoco Presents Phase I / IIa Data of IMC002 at ASCO GI 2026 , Highlighting a Durable Complete Response Beyond One Year and a 66 . 7 % ORR in Advanced GC / GEJ",
  "description": "20260113T121500Z",
  "content": "",
  "source": "manilatimes.net",
  "source_url": "https://www.manilatimes.net/2026/01/13/tmt-newswire/pr-newswire/immunofoco-presents-phase-iiia-data-of-imc002-at-asco-gi-2026-highlighting-a-durable-complete-response-beyond-one-year-and-a-667-orr-in-advanced-gcgej/2257789",
  "published_at": "20260113T121500Z",
  "fetched_at": "2026-01-14T00:24:05.619157+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "Philippines",
  "raw_data": {
    "url": "https://www.manilatimes.net/2026/01/13/tmt-newswire/pr-newswire/immunofoco-presents-phase-iiia-data-of-imc002-at-asco-gi-2026-highlighting-a-durable-complete-response-beyond-one-year-and-a-667-orr-in-advanced-gcgej/2257789",
    "url_mobile": "https://www.manilatimes.net/2026/01/13/tmt-newswire/pr-newswire/immunofoco-presents-phase-iiia-data-of-imc002-at-asco-gi-2026-highlighting-a-durable-complete-response-beyond-one-year-and-a-667-orr-in-advanced-gcgej/2257789/amp",
    "title": "Immunofoco Presents Phase I / IIa Data of IMC002 at ASCO GI 2026 , Highlighting a Durable Complete Response Beyond One Year and a 66 . 7 % ORR in Advanced GC / GEJ",
    "seendate": "20260113T121500Z",
    "socialimage": "https://www.manilatimes.net/theme_manilatimes/images/TMT_1920x1008.jpg",
    "domain": "manilatimes.net",
    "language": "English",
    "sourcecountry": "Philippines"
  }
}